11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
28 Sep
PNDORA
Goodwrench!!! Jeg er glad for, at du tjener mange penge. Jeg er glad for, at du følger en strategi, ..
62
27 Sep
OMXC20CAP
Så mangler vi bare, at du sletter din profil !   :D   Gobe
58
28 Sep
PNDORA
  Jeg har flere gange, senest den 4. juli 2016, analyseret og forklaret Pandoras forretningsmodel og..
26
28 Sep
NOVO-B
  Jeg har tidligere (blandt andet 8/8 2016) analyseret Novo og offentliggjort min beregning af, hvad..
24
25 Sep
 
Professor Jesper Rangvid fra CBS kom fredag med en stor kritik af private danske aktionærer. Han har..
14
26 Sep
SDRLO
Jeg vil gerne påtage mig selv status som euroinvestors officielle lortemand. Jeg advarer mod lorteak..
13
26 Sep
FING-B
Please, lad nu idioten være...   Det er jo kun fordi vi bliver ved med at fodre disse total idioter ..
13
26 Sep
OMXC20CAP
Er der ikke en admin eller sådan noget der kan slette baronen? Magen til evnesvag person der er yder..
13
29 Sep
ZEAL
Le petit Baron   Har du nogensinde spekuleret over hvor trættende det er, at beskæftige sig med pers..
11
29 Sep
CBRAIN
Alfen gør et seriøst stykke arbejde og er altid seriøs i debatten uden nedsættende kommentarer. Det ..
11

OZ Management LP : Form 8.3 - London Stock Exchange Group Plc

30/09/2016 13:53:39
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Admiral Group PLC : Total voting rights

30/09/2016 10:56:00
Admiral Group Plc ("the Company")  30 September 2016  Voting Rights and Capital For the purposes of the Financial Conduct Authority's Disclosure and Tr..

Form 8.5 (EPT/RI) - UK Mail Group plc

30/09/2016 07:58:41
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Zealand upsizes its private placement of new shares and shortens the offer period
2
SFL - Ship Finance International Limited Announces Offering of Convertible Senior Notes
3
Zealand raises DKK 143 million / $22 million through a private placement of new shares
4
Prothena Outlines Phase 2 Development Strategy for PRX003
5
Sun Communities, Inc. Announces Date for Third Quarter 2016 Earnings Release and Conference Call

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
30 September 2016 19:33:24
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160921.1 - EUROWEB4 - 2016-09-30 20:33:24 - 2016-09-30 19:33:24 - 1000 - Website: OKAY